@article{34b1f487966d4583aec8e2e46787f337,
title = "Identifying individuals with Alzheimer's disease-like brains based on structural imaging in the Human Connectome Project Aging cohort",
abstract = "Given the difficulty in factoring out typical age effects from subtle Alzheimer's disease (AD) effects on brain structure, identification of very early, as well as younger preclinical “at-risk” individuals has unique challenges. We examined whether age-correction procedures could be used to better identify individuals at very early potential risk from adults who did not have any existing cognitive diagnosis. First, we obtained cross-sectional age effects for each structural feature using data from a selected portion of the Human Connectome Project Aging (HCP-A) cohort. After age detrending, we weighted AD structural deterioration with patterns quantified from data of the Alzheimer's Disease Neuroimaging Initiative. Support vector machine was then used to classify individuals with brains that most resembled atrophy in AD across the entire HCP-A sample. Additionally, we iteratively adjusted the pipeline by removing individuals classified as AD-like from the HCP-A cohort to minimize atypical brain structural contributions to the age detrending. The classifier had a mean cross-validation accuracy of 94.0% for AD recognition. It also could identify mild cognitive impairment with more severe AD-specific biomarkers and worse cognition. In an independent HCP-A cohort, 8.8% were identified as AD-like, and they trended toward worse cognition. An “AD risk” score derived from the machine learning models also significantly correlated with cognition. This work provides a proof of concept for the potential to use structural brain imaging to identify asymptomatic individuals at young ages who show structural brain patterns similar to AD and are potentially at risk for a future clinical disorder.",
keywords = "Alzheimer's disease, aging, classifier, machine learning",
author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Binyin Li and Ikbeom Jang and Joost Riphagen and Randa Almaktoum and Yochim, {Kathryn Morrison} and Ances, {Beau M.} and Bookheimer, {Susan Y.} and Salat, {David H.}",
note = "Funding Information: We are grateful to all research participants and would like to thank our anonymous reviewers for their thoughtful comments on the manuscript. Data collection and sharing for ADNI in the study was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The HCP-A dataset reported in this study was supported by grants U01AG052564 and U01AG052564-S1 and by the 14 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research, by the McDonnell Center for Systems Neuroscience at Washington University, by the Office of the Provost at Washington University, and by the University of Minnesota Medical School. This study was also supported by grants from Shanghai Rising-Star Program (21QA1405800). Funding Information: Shanghai Rising‐Star Program, Grant/Award Number: 21QA1405800; University of Minnesota Medical School; McDonnell Center for Systems Neuroscience; NIH Blueprint for Neuroscience Research, Grant/Award Numbers: U01AG052564, U01AG052564‐S1; Northern California Institute for Research and Education; Foundation for the National Institutes of Health; Canadian Institutes of Health Research; Transition Therapeutics.; Takeda Pharmaceutical Company; Servier; Piramal Imaging; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Neurotrack Technologies; NeuroRx Research; Meso Scale Diagnostics, LLC; Merck & Co., Inc.; Lundbeck; Lumosity; Johnson & Johnson Pharmaceutical Research & Development LLC; Janssen Alzheimer Immunotherapy Research & Development, LLC.; IXICO Ltd.; GE Healthcare; Fujirebio Europe; Genentech, Inc.; F. Hoffmann‐La Roche Ltd; EuroImmun, L{\"u}beck, Germany; Eli Lilly and Company; Elan Pharmaceuticals, Inc.; Eisai Inc.; Cogstate; CereSpir, Inc.; Bristol‐Myers Squibb; Biogen; BioClinica, Inc.; Araclon Biotech; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; AbbVie; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Department of Defense, Grant/Award Number: W81XWH‐12‐2‐0012); Alzheimer's Disease Neuroimaging Initiative (ADNI) Funding information Funding Information: We are grateful to all research participants and would like to thank our anonymous reviewers for their thoughtful comments on the manuscript. Data collection and sharing for ADNI in the study was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The HCP‐A dataset reported in this study was supported by grants U01AG052564 and U01AG052564‐S1 and by the 14 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research, by the McDonnell Center for Systems Neuroscience at Washington University, by the Office of the Provost at Washington University, and by the University of Minnesota Medical School. This study was also supported by grants from Shanghai Rising‐Star Program (21QA1405800). Publisher Copyright: {\textcopyright} 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.",
year = "2021",
month = dec,
day = "1",
doi = "10.1002/hbm.25626",
language = "English",
volume = "42",
pages = "5535--5546",
journal = "Human Brain Mapping",
issn = "1065-9471",
number = "17",
}